Biosciences Area

  • About Biosciences
    • Leadership
    • Area Operations Centers
    • Strategic Plan and Reports
    • Strategic Programs Development Group
    • Contact Information
  • Our Science
    • Area Programs
    • Strategic Initiatives
    • Biological Systems and Engineering
    • Environmental Genomics and Systems Biology
    • Molecular Biophysics and Integrated Bioimaging
    • DOE Joint Genome Institute
  • Media and Events
    • News
    • Announcements
    • Behind the Breakthroughs
    • Events Calendar
    • Seminar Series
  • Staff Resources
    • Commonly Used Acronyms
    • Communications
    • Hiring and Recruitment
    • Hybrid & Telework Resources
    • IDEA
    • Intellectual Property, Industry Engagement, and Entrepreneurship
    • LDRD Information
    • Logos and Templates
    • Mentoring Program
  • Search

Structures Reveal New Target for Malaria Vaccine

July 20, 2018

CIS43 and CIS42 interacting with peptide 21
Computer simulations show how two antibodies—CIS43 (yellow-purple) and CIS42 (gold-green)—interact with peptide 21, a protein fragment from the malaria parasite.

With the aid of protein crystallography at the Advanced Light Source (ALS), investigators at the National Institute of Allergy and Infectious Diseases (NIAID) and the Fred Hutchinson Cancer Research Center in Seattle led a study in which they isolated human-derived antibodies that protect against malaria and determined the antibodies’ site of attack. The team isolated the antibody, called CIS43, from the blood of a volunteer who had received an experimental vaccine made from whole, weakened malaria parasites (Plasmodium falciparum). The use of a whole-parasite vaccine allowed the isolation of antibodies against circumsporozoite protein (CSP), which covers the malaria parasite in its native conformation. The scientists co-crystallized CIS43 with various peptides from CSP. Protein crystallography at ALS Beamlines 5.0.1 and 5.0.2 revealed that CIS43 works by binding to a specific portion, or epitope, of CSP. This epitope occurs only once along the length of the surface protein and is conserved across 99.8 percent of all known strains of P. falciparum. The discovery paves the way for the development of a more effective and practical human vaccine for malaria, a disease responsible for half a million deaths worldwide each year.

Read more from the ALS.

Was this page useful?

Send
like not like

About Biosciences

  • Leadership
  • Area Operations Centers
  • Inclusion, Diversity, Equity, and Accountability (IDEA)
  • Contact

Divisions & User Facility

  • Biological Systems and Engineering
  • Environmental Genomics and Systems Biology
  • Molecular Biophysics and Integrated Bioimaging
  • DOE Joint Genome Institute

Resources

  • A-Z Index
  • Phonebook
  • Logos
  • Acronyms
  • Integrated Safety Management
Questions & Comments
Follow us: Mastodon LinkedIn YouTube